Evidence map›Paper›PMID 33668707›Full record

ReviewBiology2021

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Regenerative Potential and Challenges.

Shivkanya Fuloria, Vetriselvan Subramaniyan, Rajiv Dahiya, Sunita Dahiya, Kalvatala Sudhakar, Usha Kumari, Kathiresan Sathasivam, Dhanalekshmi Unnikrishnan Meenakshi, Yuan Seng Wu, Mahendran Sekar and 3 more

Abstract readReview
In one paragraph

Review in Biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Anti-fibrotic effect ofFrontiers in bioengineering and biotechnology · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shivkanya FuloriaFaculty of Pharmacy, AIMST University, Kedah 08100, Malaysia.
Vetriselvan SubramaniyanFaculty of Medicine, Bioscience and Nursing, MAHSA University, Kuala Lumpur 42610, Malaysia.ORCID 0000-0002-9629-9494
Rajiv DahiyaSchool of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago.ORCID 0000-0002-3385-6337
Sunita DahiyaDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA.ORCID 0000-0001-7657-704X
Kalvatala SudhakarSchool of Pharmaceutical Sciences (LIT-Pharmacy), Lovely Professional University, Jalandhar 144411, India.
Usha KumariFaculty of Medicine, AIMST University, Kedah 08100, Malaysia.
Kathiresan SathasivamFaculty of Applied Science, AIMST University, Kedah 08100, Malaysia.
Dhanalekshmi Unnikrishnan MeenakshiCollege of Pharmacy, National University of Science and Technology, Muscat 130, Oman.ORCID 0000-0002-2689-4079
Yuan Seng WuFaculty of Medicine, Bioscience and Nursing, MAHSA University, Kuala Lumpur 42610, Malaysia.
Mahendran SekarFaculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh 30450, Malaysia.ORCID 0000-0002-3022-6137
Rishabha MalviyaDepartment of Pharmacy, SMAS, Galgotias University, Greater Noida 203201, India.
Amit SinghDepartment of Pharmacy, SMAS, Galgotias University, Greater Noida 203201, India.
Neeraj Kumar FuloriaFaculty of Pharmacy, AIMST University, Kedah 08100, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence suggests that stem cells exert regenerative potential via the release of extracellular vesicles. Mesenchymal stem cell extracellular vesicles (MSCEVs) offer therapeutic benefits for various pathophysiological ailments by restoring tissues. Facts suggest that MSCEV action can be potentiated by modifying the mesenchymal stem cells culturing methodology and bioengineering EVs. Limited clinical trials of MSCEVs have questioned their superiority, culturing quality, production scale-up and isolation, and administration format. Translation of preclinically successful MSCEVs into a clinical platform requires paying attention to several critical matters, such as the production technique, quantification/characterization, pharmacokinetics/targeting/transfer to the target site, and the safety profile. Keeping these issues as a priority, the present review was designed to highlight the challenges in translating preclinical MSCEV research into clinical platforms and provide evidence for the regenerative potential of MSCEVs in various conditions of the liver, kidney, heart, nervous system, bone, muscle, cartilage, and other organs/tissues.

Indexed as

cell injuryextracellular vesiclesregenerative potentialstem cellstherapeutics

Identifiers

PMID33668707
PMCPMC7996168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.